How Many Patients with Choroidal Melanoma Would Be Eligible for Neoadjuvant Systemic Therapy to Enable Ruthenium-106 Brachytherapy?
Based on the provided data and with effective neoadjuvant treatment, approximately two thirds of subjects with choroidal melanoma requiring enucleation could potentially become candidates for ruthenium-106 brachytherapy and as many as one third could also have the potential for preservation of useful vision.
Authors
- Antonio Eleuteri (ORCID: https://orcid.org/0000-0003-0718-6672)
- Bertil Damato
- Sarah E. Coupland (ORCID: https://orcid.org/0000-0002-1464-2069)
- Helen Kalirai (ORCID: https://orcid.org/0000-0002-4440-2576)
- Heinrich Heimann (ORCID: https://orcid.org/0000-0002-3298-4644)
Institutions
- Moorfields Eye Hospital NHS Foundation Trust (GB)
- University of Liverpool (GB)
- Royal Liverpool University Hospital (GB)
Publication Details
- Journal
- Cancers
- Published
- 2025-09-16
- DOI
- https://doi.org/10.3390/cancers17183022
- Citations
- 1
- Primary Topic
- Ocular Oncology and Treatments
- Type
- article
- Field-Weighted Citation Impact
- 1.71